148 related articles for article (PubMed ID: 29635611)
1. Potential of Intranasal Neuropeptide Y (NPY) and/or Melanocortin 4 Receptor (MC4R) Antagonists for Preventing or Treating PTSD.
Sabban EL; Serova LI
Mil Med; 2018 Mar; 183(suppl_1):408-412. PubMed ID: 29635611
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of intranasal neuropeptide Y and HS014 in preventing anxiety and depressive-like behavior elicited by single prolonged stress.
Sabban EL; Serova LI; Alaluf LG; Laukova M; Peddu C
Behav Brain Res; 2015 Dec; 295():9-16. PubMed ID: 25542511
[TBL] [Abstract][Full Text] [Related]
3. Locus coeruleus response to single-prolonged stress and early intervention with intranasal neuropeptide Y.
Sabban EL; Laukova M; Alaluf LG; Olsson E; Serova LI
J Neurochem; 2015 Dec; 135(5):975-86. PubMed ID: 26333000
[TBL] [Abstract][Full Text] [Related]
4. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats.
Serova LI; Tillinger A; Alaluf LG; Laukova M; Keegan K; Sabban EL
Neuroscience; 2013 Apr; 236():298-312. PubMed ID: 23376740
[TBL] [Abstract][Full Text] [Related]
5. Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats.
Laukova M; Alaluf LG; Serova LI; Arango V; Sabban EL
Endocrinology; 2014 Oct; 155(10):3920-33. PubMed ID: 25057792
[TBL] [Abstract][Full Text] [Related]
6. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model.
Serova LI; Laukova M; Alaluf LG; Pucillo L; Sabban EL
Eur Neuropsychopharmacol; 2014 Jan; 24(1):142-7. PubMed ID: 24326087
[TBL] [Abstract][Full Text] [Related]
7. Preclinical findings on the potential of intranasal neuropeptide Y for treating hyperarousal features of PTSD.
Nwokafor C; Serova LI; Sabban EL
Ann N Y Acad Sci; 2019 Nov; 1455(1):149-159. PubMed ID: 31250475
[TBL] [Abstract][Full Text] [Related]
8. Blockage of melanocortin-4 receptors by intranasal HS014 attenuates single prolonged stress-triggered changes in several brain regions.
Serova LI; Laukova M; Alaluf LG; Sabban EL
J Neurochem; 2014 Dec; 131(6):825-35. PubMed ID: 25087915
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular responses to intranasal neuropeptide Y in single prolonged stress rodent model of post-traumatic stress disorder.
Camp R; Stier CT; Serova LI; McCloskey J; Edwards JG; Reyes-Zaragoza M; Sabban EL
Neuropeptides; 2018 Feb; 67():87-94. PubMed ID: 29169656
[TBL] [Abstract][Full Text] [Related]
10. Intranasal infusion of melanocortin receptor four (MC4R) antagonist to rats ameliorates development of depression and anxiety related symptoms induced by single prolonged stress.
Serova LI; Laukova M; Alaluf LG; Sabban EL
Behav Brain Res; 2013 Aug; 250():139-47. PubMed ID: 23680165
[TBL] [Abstract][Full Text] [Related]
11. Activation of NPY receptor subtype 1 by [D-His
Nwokafor C; Serova LI; Nahvi RJ; McCloskey J; Sabban EL
Neuropeptides; 2020 Apr; 80():102001. PubMed ID: 31916978
[TBL] [Abstract][Full Text] [Related]
12. Effect of intranasal administration of neuropeptide Y and single prolonged stress on food consumption and body weight in male rats.
Serova LI; Hansson E; Sabban EL
Neuropeptides; 2020 Aug; 82():102060. PubMed ID: 32600666
[TBL] [Abstract][Full Text] [Related]
13. Potential benefits of intranasal neuropeptide Y include sustained extinction of fear memory.
Sabban EL; Serova L; Nahvi RJ; Liu X
J Neuroendocrinol; 2023 Nov; 35(11):e13279. PubMed ID: 37157881
[TBL] [Abstract][Full Text] [Related]
14. Single prolonged stress PTSD model triggers progressive severity of anxiety, altered gene expression in locus coeruleus and hypothalamus and effected sensitivity to NPY.
Serova LI; Nwokafor C; Van Bockstaele EJ; Reyes BAS; Lin X; Sabban EL
Eur Neuropsychopharmacol; 2019 Apr; 29(4):482-492. PubMed ID: 30878321
[TBL] [Abstract][Full Text] [Related]
15. Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females.
Nahvi RJ; Tanelian A; Nwokafor C; Hollander CM; Peacock L; Sabban EL
Front Behav Neurosci; 2021; 15():705579. PubMed ID: 34566592
[TBL] [Abstract][Full Text] [Related]
16. NPY1 Receptor Agonist Modulates Development of Depressive-Like Behavior and Gene Expression in Hypothalamus in SPS Rodent PTSD Model.
Serova L; Mulhall H; Sabban E
Front Neurosci; 2017; 11():203. PubMed ID: 28469551
[TBL] [Abstract][Full Text] [Related]
17. Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder.
Sabban EL; Alaluf LG; Serova LI
Neuropeptides; 2016 Apr; 56():19-24. PubMed ID: 26617395
[TBL] [Abstract][Full Text] [Related]
18. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder.
Cohen H; Liu T; Kozlovsky N; Kaplan Z; Zohar J; Mathé AA
Neuropsychopharmacology; 2012 Jan; 37(2):350-63. PubMed ID: 21976046
[TBL] [Abstract][Full Text] [Related]
19. A rodent model of traumatic stress induces lasting sleep and quantitative electroencephalographic disturbances.
Nedelcovych MT; Gould RW; Zhan X; Bubser M; Gong X; Grannan M; Thompson AT; Ivarsson M; Lindsley CW; Conn PJ; Jones CK
ACS Chem Neurosci; 2015 Mar; 6(3):485-93. PubMed ID: 25581551
[TBL] [Abstract][Full Text] [Related]
20. Re-exposure and environmental enrichment reveal NPY-Y1 as a possible target for post-traumatic stress disorder.
Hendriksen H; Bink DI; Daniels EG; Pandit R; Piriou C; Slieker R; Westphal KG; Olivier B; Oosting RS
Neuropharmacology; 2012 Sep; 63(4):733-42. PubMed ID: 22659471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
